Cargando…

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Osteosarcoma (OS) is a mesenchymal-origin tumor that constitutes the most common primary malignant bone tumor. The survival rate of the patients has significantly improved since the introduction of neoadjuvant chemotherapy and extensive resection, but it has stagnated in recent 40 years. Tyrosine ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chenglong, Shi, Qianyu, Xu, Jiuhui, Ren, Tingting, Huang, Yi, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744866/ https://www.ncbi.nlm.nih.gov/pubmed/36509754 http://dx.doi.org/10.1038/s41420-022-01252-6

Ejemplares similares

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
por: Assi, Ahmad, et al.
Publicado: (2023)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

circUSP34 accelerates osteosarcoma malignant progression by sponging miR‐16‐5p
por: Lou, Jingbing, et al.
Publicado: (2021)

Current progress and open challenges for applying deep learning across the biosciences
por: Sapoval, Nicolae, et al.
Publicado: (2022)

Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma
por: Ji, Tao, et al.
Publicado: (2023)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression
por: Xu, Jiuhui, et al.
Publicado: (2023)

A meta-analysis: the clinical value of PD-1 inhibitor or protein tyrosine kinase inhibitors in the treatment of advanced osteosarcoma
por: Shi, Binhao, et al.
Publicado: (2023)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
por: Teo, Yi Ling, et al.
Publicado: (2015)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Current understanding of tyrosine kinase BMX in inflammation and its inhibitors
por: Qiu, Le, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
por: Xu, Jiuhui, et al.
Publicado: (2023)

Immune-Related LncRNAs Affect the Prognosis of Osteosarcoma, Which Are Related to the Tumor Immune Microenvironment
por: Huang, Qingshan, et al.
Publicado: (2021)

Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects
por: Puliafito, Ivana, et al.
Publicado: (2022)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

LncRNA CASC15 is Upregulated in Osteosarcoma Plasma Exosomes and CASC15 Knockdown Inhibits Osteosarcoma Progression by Regulating miR-338-3p/RAB14 Axis
por: Zhang, Hongliang, et al.
Publicado: (2020)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer
por: Tandon, Nitin, et al.
Publicado: (2021)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Development of a Nomogram for Predicting the Efficacy of Preoperative Chemotherapy in Osteosarcoma
por: Huang, Qingshan, et al.
Publicado: (2021)

Molecular subtypes of osteosarcoma classified by cancer stem cell related genes define immunological cell infiltration and patient survival
por: Guo, Lei, et al.
Publicado: (2022)

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions
por: Žagar, Žiga, et al.
Publicado: (2023)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Activation Status of Receptor Tyrosine Kinases as an Early Predictive Marker of Response to Chemotherapy in Osteosarcoma
por: Chaiyawat, Parunya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_089pv3v12gcv9hifafdfbkon9e